Friday, February 27, 2015

Novartis lung cancer drug gets EU recommendation

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein European health regulators said on Friday they had recommended approval of a drug for advanced lung cancer developed by Swiss drugmaker Novartis that is intended to treat patients with a specific genetic mutation. It is designed for use in non-small cell lung cancer patients who have previously been treated with Pfizer's Xalkori, another ALK inhibitor. Between 2 and 7 percent of non-small cell lung cancer patients have the specific mutation of the ALK (anaplastic lymphoma kinase) protein for which such treatment is targeted.








via Health News Headlines - Yahoo News http://ift.tt/1vFC5ZE

No comments:

Post a Comment